J&J’s Darzalex Scores Again In Frontline Myeloma
But Challenger Arriving In 2020
Executive Summary
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
You may also be interested in...
GSK To Address Multiple Myeloma With First-In-Class Blenrep In EU
The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.
J&J Quickly Advances BCMA-Targeting CAR-T As JNJ-4528 Shows 100% Response
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.